Tarasi Rocco F. III sold $450K of CNO

Tarasi Rocco F. III (Chief Marketing Officer) sold 9,058 shares of CNO Financial Group, Inc. (CNO) at an average of $49.63 ($49.00–$50.00, $0.45M total) across 2 trades over 2026-06-10 to 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tarasi Rocco F. III
Published Jun 11, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CNO
Neutral
high confidence
Mentioned
$CNO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

The disclosure updates the insider ownership record and can marginally influence sentiment, but it does not introduce new operational, financial, or regulatory information.

02

Market read

A scheduled insider sale of ~$0.45M in CNO shares was filed; sentiment impact is likely small given the 10b5-1 context.

03

What to watch

Traders may still watch for clustering of insider sales across officers/directors or follow-on filings (additional Form 4s) to confirm whether selling is isolated or part of a broader pattern.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-11 (covers sales on 2026-06-10 to 2026-06-11)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for CNO Financial Group, Inc.

Company-level read

Ticker impact

$CNONeutralHigh confidence
Context

CNO Financial CMO Tarasi Rocco F. III sold $449,592 of CNO shares in two open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other news.

Evidence & confidence

The filing is an insider transaction with a stated 10b5-1 plan, and the article provides no new company fundamentals, guidance, or regulatory/legal developments.

Market effects

Minimal; this is company-specific insider activity with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

Because the trades are under a pre-arranged 10b5-1 plan, the selling may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • CNO Financial Group, Inc.

    Subject of the Form 4 insider sale by its Chief Marketing Officer.

  • Tarasi Rocco F. III

    Chief Marketing Officer who sold 9,058 CNO shares in two open-market trades.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as the basis for the insider’s sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNOMed

CNO Financial Group Inc (CNO) (Q3 2026) Earnings Call Highlights: Raised Guidance

CNO Financial Group reported Q3 2026 earnings, raising guidance. Life NAP decreased 9% due to a discontinued program. Medicare Supplement results were impacted by higher morbidity. Free cash flow guidance tightened to $220-$240M. Net investment income increased 72%, but $12M is not expected to continue. The company discussed reinsurance deals, expense management, and economic pressures. CEO Gary Bhojwani noted structural demand drivers for their services.

$CNOHighAI 8/10

CNO Financial (CNO) Q3 2026 Earnings Call Transcript

CNO Financial reported Q3 2026 earnings, highlighting 4% growth in agent count and strong sales across divisions. Medicare Supplement NAP surged 41%, and Life NAP rose 20% excluding a discontinued program. Annuity premiums increased 9%, and brokerage assets grew 15%. Operating EPS reached $1.90, up 47% YoY. The company ceded $270M in life reserves to CNO Bermuda Re for capital optimization.

$CNOMedAI 8/10

What CNO Financial Group (CNO) Said on Its Q3 Earnings Call

CNO Financial Group reported Q3 operating EPS of $1.42, up 48% YoY. Sales grew in life, hospital indemnity, and accident products. Investment income rose 13%, and the company returned $77M to shareholders. CNO updated its 2026 outlook, lowering the expense ratio and raising EPS estimates. The company also completed a reinsurance transaction with its Bermuda affiliate.